RecruitingPhase 3NCT06806592

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Boehringer Ingelheim
Intervention
Nerandomilast(drug)
Enrollment
400 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06806592 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials